aDivision of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;

bDepartment of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;

cDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY;

dDepartment of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, NY; and

eDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.

Correspondence to: Keith Sigel, MD, PhD, Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, 17 East 102nd Street, 6th Floor, New York, NY 10029; e-mail: [email protected].

National Cancer Institute P30 Center Core Grant (CA196521).

The authors have no funding or conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.drug-monitoring.com).